Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Suzette Girgis"'
Autor:
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson, Xuewen Ma, Shoba Shetty, Tong-Yuan Yang, Brandi W. Hilder, Qun Jiao, Brett Hanna, Homer C Adams, Yu-Nien Sun, Amarnath Sharma, Jennifer Smit, Jeffrey R. Infante, Jenna D. Goldberg, Yusri Elsayed
Publikováno v:
Targeted Oncology. 17:433-439
Teclistamab (JNJ-64007957), a B-cell maturation antigen × CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies.A first-in-human, Phase I, dose escalation study (MajesTEC-1) is evalua
Autor:
Roland Elmar Knoblauch, Sumit K. Subudhi, Dirk G. Brockstedt, Suzette Girgis, Enrique Zudaire, Nibedita Bandyopadhyay, Mark Wade, Jeffrey R. Infante, Russell K. Pachynski, Dolly A. Parasrampuria, Douglas G. McNeel, Nicole L. Stone, Charles G. Drake, Peter Lauer, Lawrence Fong, Gary Mason, Daniel Patricia, Todd M. Bauer, Emmanuel S. Antonarakis, Marco Gottardis
Publikováno v:
Prostate Cancer and Prostatic Diseases. 25:219-228
Background The safety and immunogenicity of JNJ-64041809 (JNJ-809), a live-attenuated, double-deleted Listeria monocytogenes (LADD Lm)-based immunotherapy targeting 4 relevant prostate cancer antigens, was evaluated in a phase 1 study in patients wit
Autor:
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson, Xuewen Ma, Shoba Shetty, Tong-Yuan Yang, Brandi W. Hilder, Qun Jiao, Brett Hanna, Homer C. Adams, Yu-Nien Sun, Amarnath Sharma, Jennifer Smit, Jeffrey R. Infante, Jenna D. Goldberg, Yusri Elsayed
Publikováno v:
Targeted Oncology. 17:609-609
Autor:
Xin Miao, Jenna D. Goldberg, Jennifer Smit, Jeffery S. Russell, Raluca Verona, Tara Stephenson, Suzette Girgis, Tineke Casneuf, Kodandaram Pillarisetti, Arnob Banerjee, Brandi Hilder, Yang Chen, Damien Fink, Diego Vieyra, Shun Xin Wang Lin
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S39-S40
Background B-cell maturation antigen (BCMA, CD269), a single transmembrane protein, can be shed as a soluble 6 kilodalton protein fragment (sBCMA) upon cleavage at the transmembrane domain by γ-secretase. Given its selective expression in the B-cell
Autor:
Thomas J. Prior, Luciano J. Costa, Monique C. Minnema, Niels W.C.J. van de Donk, Maria-Victoria Mateos, Jesus G. Berdeja, Ajai Chari, Jeffery S. Russell, Raluca Verona, Suzette Girgis, Elham Askari, Paula Rodriguez-Otero, Amrita Krishnan, A. Oriol, Brandi Hilder, Jenna D. Goldberg
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S16-S17
Background As patients (pts) with MM continue to relapse, new immunotherapy targets are needed. GPRC5D is an orphan receptor that is expressed on malignant plasma cells in MM. Talquetamab (JNJ-64407564) is a bispecific IgG4 antibody that binds to the
Autor:
Clarissa M. Uhlar, Jesús F. San-Miguel, Lotfi Benboubker, Saad Z. Usmani, Maria-Victoria Mateos, Alfred L. Garfall, Hareth Nahi, Rachel Kobos, Philippe Moreau, Rian Van Rampelbergh, Britta Besemer, Amrita Krishnan, Lionel Karlin, Jenna D. Goldberg, Laura Rosiñol, Suzette Girgis, Joaquin Martinez-Lopez, Nizar J. Bahlis, Niels W.C.J. van de Donk, Ajay K. Nooka, Albert Oriol, Lixia Pei, Thomas Martin, Arnob Banerjee, Raluca Verona, Yunsi Olyslager, Mindy Jaffe, Ajai Chari, Danielle Trancucci, Surbhi Sidana, Tara Stephenson, Rakesh Popat
Publikováno v:
Blood. 138:896-896
Introduction: Teclistamab (JNJ-64007957) is a T-cell redirecting, bispecific IgG4 antibody that targets both B-cell maturation antigen (BCMA) and CD3 receptors to induce T-cell mediated cytotoxicity of BCMA-expressing myeloma cells. Teclistamab is un
Autor:
Paula Rodriguez-Otero, Amrita Krishnan, Brandi Hilder, Elham Askari, Xuewen Ma, Shiyi Yang, Ajai Chari, Jenna D. Goldberg, Luciano J. Costa, Maria-Victoria Mateos, Suzette Girgis, Monique C. Minnema, Jesus G. Berdeja, Niels W.C.J. van de Donk, Jeffery S. Russell, Albert Oriol, Raluca Verona
Publikováno v:
Blood. 138:158-158
Introduction: Despite recent advances in treatment, patients with multiple myeloma (MM) continue to relapse. G protein-coupled receptor family C group 5 member D (GPRC5D) is a promising target for immunotherapy in patients with MM due to its high exp
Autor:
Brandi Hilder, Paula Rodriguez, Albert Oriol, Jesus G. Berdeja, Maria-Victoria Mateos, Suzette Girgis, Jeffery S. Russell, Raluca Verona, Thomas J. Prior, Monique C. Minnema, Ajai Chari, Niels W.C.J. van de Donk, Elham Askari, Amrita Krishnan, Jenna D. Goldberg
Publikováno v:
Blood. 136:40-41
Despite improved outcomes with current MM treatments, most patients (pts) will develop refractory disease, highlighting the need for novel treatments. GPRC5D is an orphan receptor whose transcript is highly expressed in primary MM cells but has gener
Autor:
Jennifer Smit, Jenna D. Goldberg, Diego Vieyra, Suzette Girgis, Tineke Casneuf, Brandi Hilder, Yang Chen, Kodandaram Pillarisetti, Jeffery S. Russell, Raluca Verona, Arnob Banerjee, Xin Miao, Tara Stephenson, Shun Xin Wang Lin, Damien Fink
Publikováno v:
Journal of Clinical Oncology. 39:8047-8047
8047 Background: B-cell maturation antigen (BCMA, CD269) is a single transmembrane protein that is selectively expressed in the B-cell lineage and is a validated target for multiple myeloma. BCMA exists as both surface protein and as a free soluble f
Autor:
Amrita Krishnan, Ajai Chari, Jesús F. San-Miguel, Tara Stephenson, Maria-Victoria Mateos, Niels W.C.J. van de Donk, Laura Rosiñol, Lotfi Benboubker, Albert Oriol, Hareth Nahi, Alfred L. Garfall, Lionel Karlin, Manisha Bhutani, Suzette Girgis, Saad Z. Usmani, Raluca Verona, Arnob Banerjee, Jenna D. Goldberg, Lixia Pei
Publikováno v:
Journal of Clinical Oncology. 39:8007-8007
8007 Background: BCMA-targeted immunotherapies offer considerable promise for relapsed/refractory MM. Teclistamab (JNJ-64007957) is a BCMA × CD3 bispecific IgG4 antibody that redirects CD3+ T cells to BCMA-expressing MM cells. We present updated res